Vista Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 384463,
    "name": "Vista Pharma.",
    "stock_name": "Vista Pharma.",
    "full_name": "Vista Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/vista-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "8.24",
    "chg": 0.44,
    "chgp": "5.64%",
    "dir": 1,
    "prev_price": "7.80",
    "mcapval": "45.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524711,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE427C01021",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "10.07 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/vista-pharma-384463-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Vista Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vista-pharma-fallingrising-3742346",
        "imagepath": "",
        "date": "2025-12-03 00:30:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Comparison</strong></p>\n<p>Vista Pharmaceuticals has experienced a sustained period of underperformance relative to the Sensex and its sector peers. Over the past week, the stock declined by 4.42%, while the Sensex advanced by 0.65%. This divergence is even more pronounced over longer time horizons. In the last month, Vista Pharma’s shares have dropped 16.29%, contrasting with a 1.43% gain in the Sensex. Year-to-date figures reveal a steep 30.22% loss for the company’s stock, whereas the benchmark index has risen by 8.96%. Over the past year, the stock has fallen 29.14%, while the Sensex gained 6.09%. Even over three and five years, Vista Pharma’s returns of 2.75% and 4.31% respectively lag significantly behind the Sensex’s robust 35.42% and 90.82% gains.<..."
      },
      {
        "title": "Why is Vista Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vista-pharma-fallingrising-3715985",
        "imagepath": "",
        "date": "2025-11-19 21:49:42",
        "description": "As of 19-Nov, Vista Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 9.18, which represents a rise of 1.53 or 20.0%. Today, the stock has outperformed its sector by 19.93% and has shown a trend reversal after two consecutive days of decline. It opened with a significant gain of 9.54% and reached an intraday high of Rs 9.18. However, despite this positive movement, the stock has been trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 25.71% compared to the 5-day average, indicating a potential concern regarding sustained interest in the stock.\n\nIn the broader market context, Vista Pharmaceuticals has underperformed compared to the Sensex over various periods, including a 3-year return of +19.22% against the Sensex's +38.15%. In the short term, the st..."
      },
      {
        "title": "Vista Pharmaceuticals Hits Upper Circuit Amidst Extraordinary Buying Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-hits-upper-circuit-amidst-unprecedented-buying-interest-3715279",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VistaPharmaceut_only_buyers_3715279.png",
        "date": "2025-11-19 12:05:13",
        "description": "Vista Pharmaceuticals Ltd witnessed an exceptional surge in buying interest on 19 Nov 2025, hitting the upper circuit with only buy orders in the queue. The stock recorded a remarkable 20.00% gain in a single trading session, significantly outperforming the Sensex’s modest 0.33% rise, signalling a potential multi-day circuit scenario driven by extraordinary demand and absence of sellers."
      },
      {
        "title": "Why is Vista Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vista-pharma-fallingrising-3712836",
        "imagepath": "",
        "date": "2025-11-18 21:47:08",
        "description": "As of 18-Nov, Vista Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 8.00, which represents a decrease of Rs. 0.39 or 4.65%. The stock has hit a new 52-week low of Rs. 7.63 today and has underperformed its sector by 4.03%. It has been on a downward trend, losing 15.07% over the last two days. Additionally, the stock has shown poor performance over various time frames, with a year-to-date decline of 32.09% and a one-year drop of 33.88%. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Although there has been a significant increase in investor participation, with delivery volume rising by 2223.84% against the 5-day average, the overall sentiment remains negative.\n\nIn the broader market context, Vista Pharmaceuticals' performance has been notably worse than the benchmark Sensex, which has gained 0..."
      },
      {
        "title": "Vista Pharmaceuticals Falls to 52-Week Low of Rs.7.63 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-falls-to-52-week-low-amidst-continued-downtrend-3712184",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VistaPharmaceut_priceRelatedfactors_3712184.png",
        "date": "2025-11-18 15:46:47",
        "description": "Vista Pharmaceuticals has reached a new 52-week low of Rs.7.63 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and valuation metrics."
      },
      {
        "title": "Why is Vista Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vista-pharma-fallingrising-3708170",
        "imagepath": "",
        "date": "2025-11-17 21:40:00",
        "description": "As of 17-Nov, Vista Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 8.39, which reflects a decrease of Rs. 1.03 or 10.93%. The stock has hit a new 52-week low of Rs. 8 today and has underperformed its sector by 11.21%. Although it opened with a gain of 3.4% and reached an intraday high of Rs. 9.9, it also saw a significant drop to an intraday low of Rs. 8, indicating high volatility with an intraday fluctuation of 10.61%. The stock has consistently underperformed over various periods, showing a year-to-date decline of 28.78% and a one-year drop of 31.51%. Additionally, it is trading below all key moving averages, which suggests a bearish trend. The delivery volume has increased significantly, indicating rising investor participation, but this has not translated into positive price movement.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has shown pos..."
      },
      {
        "title": "Vista Pharmaceuticals Hits New 52-Week Low at Rs. 8 Amid Market Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-hits-new-52-week-low-at-rs-8-amid-market-struggles-3707026",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VistaPharmaceut_priceRelatedfactors_3707026.png",
        "date": "2025-11-17 10:43:44",
        "description": "Vista Pharmaceuticals has reached a new 52-week low of Rs. 8, reflecting a significant decline in its stock performance. The company has faced a 28.49% drop over the past year, alongside ongoing financial challenges, including operating losses and a negative EBIT to Interest ratio, raising concerns about its market position."
      },
      {
        "title": "Vista Pharmaceuticals Q2 FY26: Mounting Losses Signal Deepening Operational Crisis",
        "link": "https://www.marketsmojo.com/news/result-analysis/vista-pharmaceuticals-q2-fy26-mounting-losses-signal-deepening-operational-crisis-3715887",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VistaPharmaceut_quaterlyResult_3715887.png",
        "date": "2025-11-15 09:26:51",
        "description": "Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹56.00 crores, reported catastrophic results for Q2 FY26, with net losses widening dramatically to ₹2.59 crores—a sequential deterioration of 100.78% from Q1 FY26's loss of ₹1.29 crores and a staggering 166.99% worsening compared to Q2 FY25's loss of ₹0.97 crores. The company's operational performance has collapsed into crisis territory, with operating margins plunging to an alarming -235.62% in Q2 FY26 from -73.03% in the previous quarter."
      },
      {
        "title": "How has been the historical performance of Vista Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vista-pharma-3702893",
        "imagepath": "",
        "date": "2025-11-14 23:37:15",
        "description": "Answer:\nThe historical performance of Vista Pharma shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.\n\nBreakdown:\nVista Pharma's net sales peaked at 31.07 Cr in March 2019 but have since declined sharply, reaching only 10.07 Cr in March 2025. The total operating income followed a similar pattern, dropping from 22.76 Cr in March 2020 to 10.07 Cr in March 2025. The company has consistently reported negative operating profits, with the operating profit margin excluding other income deteriorating from 3.96% in March 2019 to -40.02% in March 2025. Profit before tax has also remained negative, with a loss of -5.29 Cr in March 2025 compared to a profit of 1.15 Cr in March 2019. The profit after tax reflects this trend, showing a loss of -4.65 Cr in March 2025, down from a profit of 0.94 Cr in March 2019. The company's total liabilities have increased..."
      }
    ],
    "total": 5697,
    "sid": "384463",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/vista-pharmaceuticals-384463"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "13-Jan-2026",
      "details": "Compliance - Certificate under Reg 74(5) of SEBI (DP) Regulations",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Dec-2025",
      "details": "Closure of Trading Window",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025",
      "datetime": "13-Nov-2025",
      "details": "Un audited financial Results for the quarter and half year ended 30.09.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Vista Pharma. falling/rising?

2025-12-03 00:30:45

Recent Price Performance and Market Comparison Vista Pharmaceuticals has experienced a sustained period of underperformance relative to the Sensex and its sector peers. Over the past week, the stock declined by 4.42%, while the Sensex advanced by 0.65%. This divergence is even more pronounced over longer time horizons. In the last month, Vista Pharma’s shares have dropped 16.29%, contrasting with a 1.43% gain in the Sensex. Year-to-date figures reveal a steep 30.22% loss for the company’s stock, whereas the benchmark index has risen by 8.96%. Over the past year, the stock has fallen 29.14%, while the Sensex gained 6.09%. Even over three and five years, Vista Pharma’s returns of 2.75% and 4.31% respectively lag significantly behind the Sensex’s robust 35.42% and 90.82% gains.<...

Why is Vista Pharma. falling/rising?

2025-11-19 21:49:42

As of 19-Nov, Vista Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 9.18, which represents a rise of 1.53 or 20.0%. Today, the stock has outperformed its sector by 19.93% and has shown a trend reversal after two consecutive days of decline. It opened with a significant gain of 9.54% and reached an intraday high of Rs 9.18. However, despite this positive movement, the stock has been trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 25.71% compared to the 5-day average, indicating a potential concern regarding sustained interest in the stock. In the broader market context, Vista Pharmaceuticals has underperformed compared to the Sensex over various periods, including a 3-year return of +19.22% against the Sensex's +38.15%. In the short term, the st...

Vista Pharmaceuticals Hits Upper Circuit Amidst Extraordinary Buying Interest

2025-11-19 12:05:13

Vista Pharmaceuticals Ltd witnessed an exceptional surge in buying interest on 19 Nov 2025, hitting the upper circuit with only buy orders in the queue. The stock recorded a remarkable 20.00% gain in a single trading session, significantly outperforming the Sensex’s modest 0.33% rise, signalling a potential multi-day circuit scenario driven by extraordinary demand and absence of sellers.

Why is Vista Pharma. falling/rising?

2025-11-18 21:47:08

As of 18-Nov, Vista Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 8.00, which represents a decrease of Rs. 0.39 or 4.65%. The stock has hit a new 52-week low of Rs. 7.63 today and has underperformed its sector by 4.03%. It has been on a downward trend, losing 15.07% over the last two days. Additionally, the stock has shown poor performance over various time frames, with a year-to-date decline of 32.09% and a one-year drop of 33.88%. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Although there has been a significant increase in investor participation, with delivery volume rising by 2223.84% against the 5-day average, the overall sentiment remains negative. In the broader market context, Vista Pharmaceuticals' performance has been notably worse than the benchmark Sensex, which has gained 0...

Vista Pharmaceuticals Falls to 52-Week Low of Rs.7.63 Amidst Continued Downtrend

2025-11-18 15:46:47

Vista Pharmaceuticals has reached a new 52-week low of Rs.7.63 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and valuation metrics.

Why is Vista Pharma. falling/rising?

2025-11-17 21:40:00

As of 17-Nov, Vista Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 8.39, which reflects a decrease of Rs. 1.03 or 10.93%. The stock has hit a new 52-week low of Rs. 8 today and has underperformed its sector by 11.21%. Although it opened with a gain of 3.4% and reached an intraday high of Rs. 9.9, it also saw a significant drop to an intraday low of Rs. 8, indicating high volatility with an intraday fluctuation of 10.61%. The stock has consistently underperformed over various periods, showing a year-to-date decline of 28.78% and a one-year drop of 31.51%. Additionally, it is trading below all key moving averages, which suggests a bearish trend. The delivery volume has increased significantly, indicating rising investor participation, but this has not translated into positive price movement. Broader Market Context: In comparison to the benchmark Sensex, which has shown pos...

Vista Pharmaceuticals Hits New 52-Week Low at Rs. 8 Amid Market Struggles

2025-11-17 10:43:44

Vista Pharmaceuticals has reached a new 52-week low of Rs. 8, reflecting a significant decline in its stock performance. The company has faced a 28.49% drop over the past year, alongside ongoing financial challenges, including operating losses and a negative EBIT to Interest ratio, raising concerns about its market position.

Vista Pharmaceuticals Q2 FY26: Mounting Losses Signal Deepening Operational Crisis

2025-11-15 09:26:51

Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹56.00 crores, reported catastrophic results for Q2 FY26, with net losses widening dramatically to ₹2.59 crores—a sequential deterioration of 100.78% from Q1 FY26's loss of ₹1.29 crores and a staggering 166.99% worsening compared to Q2 FY25's loss of ₹0.97 crores. The company's operational performance has collapsed into crisis territory, with operating margins plunging to an alarming -235.62% in Q2 FY26 from -73.03% in the previous quarter.

How has been the historical performance of Vista Pharma.?

2025-11-14 23:37:15

Answer: The historical performance of Vista Pharma shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods. Breakdown: Vista Pharma's net sales peaked at 31.07 Cr in March 2019 but have since declined sharply, reaching only 10.07 Cr in March 2025. The total operating income followed a similar pattern, dropping from 22.76 Cr in March 2020 to 10.07 Cr in March 2025. The company has consistently reported negative operating profits, with the operating profit margin excluding other income deteriorating from 3.96% in March 2019 to -40.02% in March 2025. Profit before tax has also remained negative, with a loss of -5.29 Cr in March 2025 compared to a profit of 1.15 Cr in March 2019. The profit after tax reflects this trend, showing a loss of -4.65 Cr in March 2025, down from a profit of 0.94 Cr in March 2019. The company's total liabilities have increased...

View All News